Expression of integrin α 
        vβ
        3 in medullary thyroid carcinoma.

Lisa H de Vries; Lutske Lodewijk; Emma W Pijnappel; Paul J van Diest; Abbey Schepers; Han J Bonenkamp; Ilse Ach van Engen-van Grunsven; Schelto Kruijff; Bettien M van Hemel; Thera P Links; Els Jm Nieveen van Dijkum; Susanne van Eeden; Rachel S van Leeuwaarde; Gerlof D Valk; Bart de Keizer; Inne Hm Borel Rinkes; Menno R Vriens

doi:10.1080/14796694.2024.2376511

Expression of integrin α vβ 3 in medullary thyroid carcinoma.

Lisa H de Vries, Lutske Lodewijk, Emma W Pijnappel, Paul J van Diest, Abbey Schepers, Han J Bonenkamp, Ilse Ach van Engen-van Grunsven, Schelto Kruijff, Bettien M van Hemel, Thera P Links, Els Jm Nieveen van Dijkum, Susanne van Eeden, Rachel S van Leeuwaarde, Gerlof D Valk, Bart de Keizer, Inne Hm Borel Rinkes, Menno R Vriens

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aim: Tumor markers often remain elevated after intended curative resection of medullary thyroid carcinoma (MTC). The aim of this study was to determine the expression of α vβ 3, a promising theranostics target, in MTC and its metastases. Materials & methods: A vβ 3 expression was analyzed in 104 patients using a tissue microarray and correlated with clinicopathological variables and survival. Results: Cytoplasmic α vβ 3 positivity was seen in 70 patients and was associated with lymph node metastases at time of initial surgery. Membranous positivity was considered positive in 30 patients and was associated with sporadic MTC. Conclusion: A vβ 3 was expressed in the cytoplasm of 67% of MTC patients. Membranous expression, which is presumably most relevant for the theranostic use of α vβ 3, was seen in 29%.

Original language	English
Pages (from-to)	2015-2022
Number of pages	8
Journal	Future Oncology
Volume	20
Issue number	27
Early online date	5 Aug 2024
DOIs	https://doi.org/10.1080/14796694.2024.2376511
Publication status	Published - 2024

Keywords

medullary thyroid carcinoma
nuclear imaging
nuclear therapy
tissue microarray
α β

Access to Document

10.1080/14796694.2024.2376511Licence: CC BY-NC-ND

Expression of integrin v 3 in medullary thyroid carcinomaFinal published version, 1.39 MBLicence: CC BY-NC-ND

Cite this

de Vries, L. H., Lodewijk, L., Pijnappel, E. W., van Diest, P. J., Schepers, A., Bonenkamp, H. J., van Engen-van Grunsven, I. A., Kruijff, S., van Hemel, B. M., Links, T. P., Nieveen van Dijkum, E. J., Eeden, S. V., van Leeuwaarde, R. S., Valk, G. D., Keizer, B. D., Borel Rinkes, I. H., & Vriens, M. R. (2024). Expression of integrin α vβ 3 in medullary thyroid carcinoma. Future Oncology, 20(27), 2015-2022. https://doi.org/10.1080/14796694.2024.2376511

@article{953f287ec3574041acc0585d303ece3c,

title = "Expression of integrin α vβ 3 in medullary thyroid carcinoma.",

abstract = " Aim: Tumor markers often remain elevated after intended curative resection of medullary thyroid carcinoma (MTC). The aim of this study was to determine the expression of α vβ 3, a promising theranostics target, in MTC and its metastases. Materials & methods: A vβ 3 expression was analyzed in 104 patients using a tissue microarray and correlated with clinicopathological variables and survival. Results: Cytoplasmic α vβ 3 positivity was seen in 70 patients and was associated with lymph node metastases at time of initial surgery. Membranous positivity was considered positive in 30 patients and was associated with sporadic MTC. Conclusion: A vβ 3 was expressed in the cytoplasm of 67% of MTC patients. Membranous expression, which is presumably most relevant for the theranostic use of α vβ 3, was seen in 29%. ",

keywords = "medullary thyroid carcinoma, nuclear imaging, nuclear therapy, tissue microarray, α β",

author = "{de Vries}, {Lisa H} and Lutske Lodewijk and Pijnappel, {Emma W} and {van Diest}, {Paul J} and Abbey Schepers and Bonenkamp, {Han J} and {van Engen-van Grunsven}, {Ilse Ach} and Schelto Kruijff and {van Hemel}, {Bettien M} and Links, {Thera P} and {Nieveen van Dijkum}, {Els Jm} and Eeden, {Susanne van} and {van Leeuwaarde}, {Rachel S} and Valk, {Gerlof D} and Keizer, {Bart de} and {Borel Rinkes}, {Inne Hm} and Vriens, {Menno R}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2024",

doi = "10.1080/14796694.2024.2376511",

language = "English",

volume = "20",

pages = "2015--2022",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "27",

}

de Vries, LH, Lodewijk, L, Pijnappel, EW, van Diest, PJ, Schepers, A, Bonenkamp, HJ, van Engen-van Grunsven, IA, Kruijff, S, van Hemel, BM, Links, TP, Nieveen van Dijkum, EJ, Eeden, SV, van Leeuwaarde, RS , Valk, GD , Keizer, BD, Borel Rinkes, IH & Vriens, MR 2024, 'Expression of integrin α vβ 3 in medullary thyroid carcinoma.', Future Oncology, vol. 20, no. 27, pp. 2015-2022. https://doi.org/10.1080/14796694.2024.2376511

TY - JOUR

T1 - Expression of integrin α vβ 3 in medullary thyroid carcinoma.

AU - de Vries, Lisa H

AU - Lodewijk, Lutske

AU - Pijnappel, Emma W

AU - van Diest, Paul J

AU - Schepers, Abbey

AU - Bonenkamp, Han J

AU - van Engen-van Grunsven, Ilse Ach

AU - Kruijff, Schelto

AU - van Hemel, Bettien M

AU - Links, Thera P

AU - Nieveen van Dijkum, Els Jm

AU - Eeden, Susanne van

AU - van Leeuwaarde, Rachel S

AU - Valk, Gerlof D

AU - Keizer, Bart de

AU - Borel Rinkes, Inne Hm

AU - Vriens, Menno R

PY - 2024

Y1 - 2024

N2 - Aim: Tumor markers often remain elevated after intended curative resection of medullary thyroid carcinoma (MTC). The aim of this study was to determine the expression of α vβ 3, a promising theranostics target, in MTC and its metastases. Materials & methods: A vβ 3 expression was analyzed in 104 patients using a tissue microarray and correlated with clinicopathological variables and survival. Results: Cytoplasmic α vβ 3 positivity was seen in 70 patients and was associated with lymph node metastases at time of initial surgery. Membranous positivity was considered positive in 30 patients and was associated with sporadic MTC. Conclusion: A vβ 3 was expressed in the cytoplasm of 67% of MTC patients. Membranous expression, which is presumably most relevant for the theranostic use of α vβ 3, was seen in 29%.

AB - Aim: Tumor markers often remain elevated after intended curative resection of medullary thyroid carcinoma (MTC). The aim of this study was to determine the expression of α vβ 3, a promising theranostics target, in MTC and its metastases. Materials & methods: A vβ 3 expression was analyzed in 104 patients using a tissue microarray and correlated with clinicopathological variables and survival. Results: Cytoplasmic α vβ 3 positivity was seen in 70 patients and was associated with lymph node metastases at time of initial surgery. Membranous positivity was considered positive in 30 patients and was associated with sporadic MTC. Conclusion: A vβ 3 was expressed in the cytoplasm of 67% of MTC patients. Membranous expression, which is presumably most relevant for the theranostic use of α vβ 3, was seen in 29%.

KW - medullary thyroid carcinoma

KW - nuclear imaging

KW - nuclear therapy

KW - tissue microarray

KW - α β

UR - http://www.scopus.com/inward/record.url?scp=85200436138&partnerID=8YFLogxK

U2 - 10.1080/14796694.2024.2376511

DO - 10.1080/14796694.2024.2376511

M3 - Article

C2 - 39101553

SN - 1479-6694

VL - 20

SP - 2015

EP - 2022

JO - Future Oncology

JF - Future Oncology

IS - 27

ER -

Expression of integrin α vβ 3 in medullary thyroid carcinoma.

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this